Capital Midwest Fund leads Series C round for ProNAi Therapeutics

ProNAi Therapeutics has raised over $12 million in Series C financing. Capital Midwest Fund led the round. Based in Plymouth, Michigan, ProNAi Therapeutics is a biopharmaceutical company focused on developing treatments for cancer patients and others with complex genetic diseases.

North AmericaUSBriefs